Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped

Sanofi had hoped the acquisition of Kymab would fill a major hole that will be left as autoimmune juggernaut Dupixent heads toward a patent cliff. Now, another therapy has failed to meet expectations.